Navigation Links
Mast Therapeutics Prices Public Offering Of Units
Date:6/14/2013

he final prospectus may be obtained by contacting: Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by e-mail at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). 

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014.  More information can be found on the Company's web site at www.masttherapeutics.com.

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mas
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... City, CA (PRWEB) August 28, 2014 ... sanitation products for the food processing industry, is asking ... a side-by side comparison of the E2 soap they’re ... E2 Sanitizing Foam Soap . Hand hygiene is ... in the food processing environment. Six key criteria are ...
(Date:8/28/2014)... LAFAYETTE, Ind. A new research platform ... properties of tiny structures undergoing stress and ... to improve designs for microelectronics and batteries., ... reveals information about how heating and the ... mechanical properties. Researchers have discussed the merits ...
(Date:8/28/2014)... The ability for organizations to attract ... allow individuals to perform at the highest of levels, ... looking to compete in this post–recession era. The ... as the sector increasingly focuses on the importance of ... have real results on the organization's development and the ...
(Date:8/28/2014)... Kent, WA (PRWEB) August 28, 2014 ... Synder Filtration’s polymeric membranes to its stable of ... of available molecular weight cut-offs and include membrane filters ... a steady increase in customer demand for our membrane ... a greater variety of flat sheet membranes,” explains Sterlitech ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2
... May 17, 2011 Brian Olson didn,t exactly fit the image ... be the first to admit it. "I had just a GED ... into remedial math." With a vague notion that he ... of," Olson enrolled in basic chemistry and biology courses as a ...
... May 17, 2011 P f enex ... has submitted a Biologics Master File (BMF) to the United ... carrier protein to support the development of conjugate vaccine products ... supplying cGMP grade CRM197 carrier protein to multiple partners in ...
... Mich., May 17, 2011 Neogen Corporation (Nasdaq: ... retired senior vice president of The Kroger Co. and former ... elected to Neogen,s Board of Directors. "Since our ... quality of individuals on our Board of Directors, and the ...
Cached Biology Technology:From GED to PhD: Borough of Manhattan Community College's Brian Olson Faces Academic Deficits Only to Be Rewarded with Acceptance to CUNY's PhD Program in Biochemistry 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3William T. Boehm Joins Neogen's Board of Directors 2
(Date:8/28/2014)... than traditional cigarettes, but still release toxins into ... USC. , Scientists studying secondhand smoke from e-cigarettes ... harmful particles, with close-to-zero exposure to organic carcinogens. ... in second-hand e-cigarette smoke were found to be ... levels of polycyclic aromatic hydrocarbons cancer-causing organic ...
(Date:8/28/2014)... researcher and his collaborators have developed an online analytic ... of re-engineering cells for biomedical investigation. CellNet is a ... aid stem cell engineering. Details of CellNet and its ... back-to-back papers in the journal Cell . , ... for all types of cell-based investigations and can potentially ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Genetics Society of America,s 27th Annual Mouse Molecular ... 2014 in Pacific Grove, California. These awards ... post doctorates and scientists from underrepresented groups into ... to encourage the participation of young scientists at ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2New tool aids stem cell engineering for medical research 2
... to be launched on Tuesday 14 February at the Lions ... hundreds of Victorians a year by extending the time between ... the new facilities, LCDS can now store corneas at human ... Previously, corneas were held at low temperatures and had to ...
... at improving the prevention, diagnosis and treatment of cancer, ... launched this week after several years of meticulous planning. ... south Manchester area are being given the opportunity to ... year. , They are being sent invitations to take ...
... director at the Max Planck Institute of Biochemistry in ... 1990s that blocking blood vessel development in a tumour ... fundamental principle led to the development of SUTENT®, whose ... clinical use in the United States, and it is ...
Cached Biology News:Australian first to save sight 2Multi-million pound UK Biobank underway 2Multi-million pound UK Biobank underway 3Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4
... Microarray Hybridization Wash Pack provides optimized ... slides. Preparation Quality Clarifier: Ready-to-use wash ... with SigmaScreen(tm) APS Coated Slides for ... Microarray Hybridization Blocking Buffer: 1L • ...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: